<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="ribavirin/PMC5228644/results/search/drugs/results.xml">
  <result pre="Study Assessment of hepatocellular carcinoma risk based on peg-interferon plus" exact="ribavirin" post="treatment experience in this new era of highly effective"/>
  <result pre="This study undertaken to identify suitable candidates for peg-interferon plus" exact="ribavirin" post="(PEG-IFN/RBV) treatment by evaluating hepatocellular carcinoma (HCC) risk in"/>
  <result pre="CHC do not receive antiviral therapy.[1] Moreover, previous peg-interferon plus" exact="ribavirin" post="(PEG-IFN/RBV)-based regimens are less effective and have higher side"/>
  <result pre="FDA approved of DAAs in 2011, new drugs, such as" exact="sofosbuvir" post="and daclatasvir/asunaprevir, were recently approved with much higher SVR"/>
  <result pre="C virus infection. Lancet Infect Dis2005;5:558–67.16122679 [3]MannsMPMcHutchisonJGGordonSCet al.Peginterferon alfa-2b plus" exact="ribavirin" post="compared with interferon alfa-2b plus ribavirin for initial treatment"/>
  <result pre="[3]MannsMPMcHutchisonJGGordonSCet al.Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus" exact="ribavirin" post="for initial treatment of chronic hepatitis C: a randomised"/>
  <result pre="hepatitis C: a randomised trial. Lancet2001;358:958–65.11583749 [4]FriedMWShiffmanMLReddyKRet al.Peginterferon alfa-2a plus" exact="ribavirin" post="for chronic hepatitis C virus infection. N Engl J"/>
  <result pre="Engl J Med2002;347:975–82.12324553 [5]KhurooMSKhurooMSDahabSTMeta-analysis: a randomized trial of peginterferon plus" exact="ribavirin" post="for the initial treatment of chronic hepatitis C genotype"/>
  <result pre="Clin Mol Hepatol2016;22:76–139.27044763 [10]HungCHLeeCMLuSNet al.Long-term effect of interferon alpha-2b plus" exact="ribavirin" post="therapy on incidence of hepatocellular carcinoma in patients with"/>
  <result pre="pegylated interferon and ribavirin. Dig Dis Sci2015;60:573–81.25236421 [17]HondaTIshigamiMMasudaHet al.Effect of" exact="peginterferon alfa-2b" post="and ribavirin on hepatocellular carcinoma prevention in older patients"/>
  <result pre="ribavirin. Dig Dis Sci2015;60:573–81.25236421 [17]HondaTIshigamiMMasudaHet al.Effect of peginterferon alfa-2b and" exact="ribavirin" post="on hepatocellular carcinoma prevention in older patients with chronic"/>
  <result pre="J Gastroenterol Hepatol2015;30:1281–7.25778783 [19]OgawaEFurusyoNKajiwaraEet al.Efficacy of pegylated interferon alpha-2b and" exact="ribavirin" post="treatment on the risk of hepatocellular carcinoma in patients"/>
  <result pre="C: a prospective, multicenter study. J Hepatol2013;58:495–501.23099187 [20]Fernandez-RodriguezCMAlonsoSMartinezSMet al.Peginterferon plus" exact="ribavirin" post="and sustained virological response in HCV-related cirrhosis: outcomes and"/>
  <result pre="predicting response. Am J Gastroenterol2010;105:2164–72.20700116 [21]CardosoACMoucariRFigueiredo-MendesCet al.Impact of peginterferon and" exact="ribavirin" post="therapy on hepatocellular carcinoma: incidence and survival in hepatitis"/>
  <result pre="sonographic study of the liver surface. Radiology1989;172:389–92.2526349 [24]AfdhalNZeuzemSKwoPet al.Ledipasvir and" exact="sofosbuvir" post="for untreated HCV genotype 1 infection. N Engl J"/>
  <result pre="effects of therapy for chronic hepatitis C. Gastroenterology2003;124:1711–9.12761728 [28]MannsMPolSJacobsonIMet al.All-oral" exact="daclatasvir" post="plus asunaprevir for hepatitis C virus genotype 1b: a"/>
  <result pre="phase 3, multicohort study. Lancet2014;384:1597–605.25078304 [29]CapraruCIKuczynskiMLaDet al.Efficacy and safety of" exact="sofosbuvir" post="plus simeprevir in patients with advanced HCV cirrhosis. Hepatology2014;60:665a."/>
  <result pre="multicohort study. Lancet2014;384:1597–605.25078304 [29]CapraruCIKuczynskiMLaDet al.Efficacy and safety of sofosbuvir plus" exact="simeprevir" post="in patients with advanced HCV cirrhosis. Hepatology2014;60:665a. [30]GonzalesGRGonzalezSANazarioHEet al.Efficacy"/>
  <result pre="Hepatology2014;60:665a. [30]GonzalesGRGonzalezSANazarioHEet al.Efficacy of Ledipasvir plus Sofosobuvir with or without" exact="ribavirin" post="in hepatitis C genotype 1 patients who failed previous"/>
  <result pre="Hepatology2015;62:775a. [31]JinYJLeeJWLeeJIet al.Multicenter comparison of PEG-IFN alpha2a or alpha2b plus" exact="ribavirin" post="for treatment-naive HCV patient in Korean population. BMC Gastroenterol2013;13:74.23627926"/>
  <result pre="in Korean population. BMC Gastroenterol2013;13:74.23627926 [32]HondaTKatanoYShimizuJet al.Efficacy of peginterferon-alpha-2b plus" exact="ribavirin" post="in patients aged 65 years and older with chronic"/>
  <result pre="the elderly. Dig Dis Sci2015;60:3170–80.26008618 [35]ModiAANazarioHTrotterJFet al.Safety and efficacy of" exact="simeprevir" post="plus sofosbuvir with or without ribavirin in patients with"/>
  <result pre="Dig Dis Sci2015;60:3170–80.26008618 [35]ModiAANazarioHTrotterJFet al.Safety and efficacy of simeprevir plus" exact="sofosbuvir" post="with or without ribavirin in patients with decompensated genotype"/>
  <result pre="al.Safety and efficacy of simeprevir plus sofosbuvir with or without" exact="ribavirin" post="in patients with decompensated genotype 1 hepatitis C cirrhosis."/>
  <result pre="hepatitis C cirrhosis. Liver Transplant2016;22:281–6. [36]MorenoCLasserLDelwaideJet al.Sofosbuvir in combination with" exact="simeprevir" post="+/− ribavirin in genotype 4 hepatitis C patients with"/>
  <result pre="cirrhosis. Liver Transplant2016;22:281–6. [36]MorenoCLasserLDelwaideJet al.Sofosbuvir in combination with simeprevir +/−" exact="ribavirin" post="in genotype 4 hepatitis C patients with advanced fibrosis"/>
 </snippets>
</snippetsTree>
